



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: PRTA

Last Trade:	39.95
Trade Time:	4:00 PM ET Jan 16, 2018
Change:	-1.38 (-3.339%)
Day Range	39.77 - 43.35
52-Week Range	34.85 - 70.00
Volume	576,260

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jan 3, 2018

[Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference](#)

Nov 22, 2017

[Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

Nov 16, 2017

[Prothena Highlights Breadth of Novel Pipeline at R&D Day](#)

Nov 7, 2017

[Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update](#)

Nov 1, 2017

[Prothena to Participate in the Credit Suisse 26th Annual Healthcare Conference](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Feb 27, 2017

[Annual Report \(10-K\)](#)

Mar 31, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)